Yap, Y. S., Li, H., Zhang, Q., Sunpaweravong, P., Leung, R. C., Samdaengpan, C., Chung, C., Wang, X., Jung, K. H., Teh, H. L., Tseng, L., Chua, N., Jin, Y., Clark, T. D., Im, S. (2026). INAVO120 phase 3 trial: Subgroup analyses of Asian patients (pts) with
                    <i>PIK3CA</i>
                    -mutated (mut), hormone receptor-positive, HER2-negative (HER2–), endocrine-resistant advanced breast cancer (aBC) treated with inavolisib (INAVO)/placebo (PBO) + palbociclib (PALBO) + fulvestrant (FULV).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.19_suppl.28